Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir.
作者信息
Ueda Munetaka, Tanimoto Tetsuya, Murayama Anju, Ozaki Akihiko, Kami Masahiro
机构信息
Japanese Red Cross Medical Center, Tokyo, Japan.
Navitas Clinic Kawasaki, Kawasaki, Japan.
出版信息
Clin Pharmacol Ther. 2022 Mar;111(3):545-547. doi: 10.1002/cpt.2251. Epub 2021 Apr 21.
Abstract
摘要
相似文献
1
Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir.新冠疫情期间日本的药品监管：法匹拉韦案例研究的经验教训
Clin Pharmacol Ther. 2022 Mar;111(3):545-547. doi: 10.1002/cpt.2251. Epub 2021 Apr 21.
2
Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.采用瑞德西韦和法匹拉韦作为治疗选择应对 COVID-19。
Chembiochem. 2021 Mar 16;22(6):939-948. doi: 10.1002/cbic.202000595. Epub 2020 Nov 11.
3
Scientists criticize use of unproven COVID drugs in India.科学家批评印度使用未经证实的新冠药物。
Nature. 2020 Nov;587(7833):187-188. doi: 10.1038/d41586-020-03105-7.
4
Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.瑞德西韦和法匹拉韦治疗 COVID-19 的心血管注意事项。
Cardiovasc Hematol Disord Drug Targets. 2021;21(2):88-90. doi: 10.2174/1871529X21666210812103535.
5
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.治疗 SARS-CoV-2 感染的困境：法匹拉韦与瑞德西韦。
Biomed Pharmacother. 2022 Mar;147:112700. doi: 10.1016/j.biopha.2022.112700. Epub 2022 Feb 4.
6
FDA Approval of Remdesivir - A Step in the Right Direction.美国食品药品监督管理局对瑞德西韦的批准——朝着正确方向迈出的一步。
N Engl J Med. 2020 Dec 31;383(27):2598-2600. doi: 10.1056/NEJMp2032369. Epub 2020 Dec 2.
7
Regulatory approval for COVID-19 across the globe.全球范围内对新冠病毒病的监管批准。
Indian J Pharmacol. 2020 Nov-Dec;52(6):457-466. doi: 10.4103/ijp.ijp_32_21.
8
The Challenges Ahead With Monoclonal Antibodies: From Authorization to Access.单克隆抗体面临的未来挑战：从获批到可及性
JAMA. 2020 Dec 1;324(21):2151-2152. doi: 10.1001/jama.2020.21872.
9
COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review.新型冠状病毒肺炎：分子病理生理学、遗传进化与展望治疗策略——综述。
Arch Microbiol. 2021 Jul;203(5):2043-2057. doi: 10.1007/s00203-021-02183-z. Epub 2021 Feb 8.
10
Clinical pharmacodynamics of obeldesivir versus remdesivir.奥贝德西韦与瑞德西韦的临床药效学
Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0096924. doi: 10.1128/aac.00969-24. Epub 2024 Aug 12.
引用本文的文献
1
Dysregulated glycerophospholipid metabolism in amygdala may mediate favipiravir-induced anxiety-like behaviors in mice.杏仁核中甘油磷脂代谢失调可能介导了法匹拉韦诱导的小鼠焦虑样行为。
Front Pharmacol. 2025 Mar 4;16:1491150. doi: 10.3389/fphar.2025.1491150. eCollection 2025.
2
Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID).法匹拉韦在新冠肺炎肺炎患者中的安全性和有效性。一项随机、双盲、安慰剂对照研究（FAVID）。
Pneumonia (Nathan). 2024 Feb 25;16(1):3. doi: 10.1186/s41479-023-00124-6.
3
Impact of common comorbidities on antimicrobial consumption and mortality amongst critically ill COVID-19 patients: A retrospective two center study in Saudi Arabia.常见合并症对危重症COVID-19患者抗菌药物使用及死亡率的影响：沙特阿拉伯一项双中心回顾性研究
Clin Infect Pract. 2023 Jul;19:100229. doi: 10.1016/j.clinpr.2023.100229. Epub 2023 May 4.
4
Therapeutics for COVID-19.治疗 COVID-19 的方法。
Nat Microbiol. 2023 May;8(5):771-786. doi: 10.1038/s41564-023-01356-4. Epub 2023 May 4.
5
Antiviral Potential of Natural Resources against Influenza Virus Infections.自然资源抗流感病毒感染的抗病毒潜力。
Viruses. 2022 Nov 5;14(11):2452. doi: 10.3390/v14112452.
6
Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia.法匹拉韦在住院中重度新冠肺炎患者中的有效性和安全性：沙特阿拉伯的前瞻性多中心观察性研究
Front Med (Lausanne). 2022 Mar 4;9:826247. doi: 10.3389/fmed.2022.826247. eCollection 2022.
7
An update of anti-viral treatment of COVID-19.新型冠状病毒肺炎抗病毒治疗的更新。
Turk J Med Sci. 2021 Dec 17;51(SI-1):3372-3390. doi: 10.3906/sag-2106-250.
本文引用的文献
1
Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval.COVID-19大流行期间的紧急使用授权：羟氯喹用于疫苗授权和批准的经验教训。
JAMA. 2020 Oct 6;324(13):1282-1283. doi: 10.1001/jama.2020.16253.
2
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
3
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
Zotero 插件